Rumors about the astonishing weight loss potential of Eli Lilly's triple hormone drug retatrutide have been circulating for months. The results of its Phase 3 clinical trial, just released by the ...

Retatrutide, a powerful experimental weight-loss drug that mimics three different hormones the body produces after eating, helped people lose 70 pounds on average, or 28% of their body weight, ...

As Eli Lilly looks to hold its lead in the lucrative obesity market, the company’s next-gen prospect, the triple-G drug retatrutide, has met the primary endpoint for weight loss in another pivotal ...

At the NAB Show in Las Vegas last month, Pearl TV, the consortium of broadcasters, manufacturers and industry advocates showcased prototypes of new converter boxes that would allow consumers to ...

"Ozempic face," "Ozempic butt," "Ozempic breath," even "Ozempic feet" — as those using GLP-1 medications for weight loss probably already know, people can be tough on them, even with the skyrocketing ...

WeightWatchers' Core+ program offers personalized weight loss support starting at $20 per month. The program focuses on nutrition, habit-building and community support. Core+ features specialized ...

NASHVILLE, Tenn. (WSMV) - Tennessee lawmakers have passed a bill that would require sheriffs of each county to enter an agreement under an available federal 287(g) immigration enforcement program by ...

Medicare has delayed a program for older Americans that would've required participating insurance companies to cover GLP-1 weight loss drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound.

Demand for weight loss drugs is ballooning across the U.S. — and Amazon wants in. The Seattle-based tech giant launched its own GLP-1 program Tuesday aimed at streamlining access to weight loss drugs, ...